Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03615924 · ClinicalTrials.gov registry record · Phase 3
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
NCT03615924 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 193 participants.
The verdict
NCT03615924, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
Study Summary
The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease
Interventions
- DRUG Placebo
- DRUG Ticagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03615924
The ClinicalTrials.gov registry entry for NCT03615924 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03615924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03615924 about?
NCT03615924 is a clinical study titled "Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease". The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease
What is the current status of trial NCT03615924?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2018-09-26. Estimated completion is 2020-08-13.
What interventions are being tested in trial NCT03615924?
The interventions under investigation include: Placebo (DRUG), Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT03615924?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.